Trial Profile
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone Acetate and Apalutamide (ARN-509) for Rising PSA After Radical Prostatectomy With Adverse Features.(FORMULA-509 Trial)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Apalutamide (Primary) ; Bicalutamide; Gonadotropin releasing hormone; Prednisone
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms FORMULA-509
- 27 Jan 2024 Results of Patient-reported health-related quality of life , presented at the 2024 Genitourinary Cancers Symposium
- 18 Feb 2023 Primary endpoint (PSA Progression Free Survival) has not been met, as per results presented at the 2023 Genitourinary Cancers Symposium.
- 18 Feb 2023 Results assessing the efficacy and safety of abiraterone acetate/prednisone (AAP) and apalutamide (Apa) in patients with post-radical prostatectomy, presented at the 2023 Genitourinary Cancers Symposium.